The March 2026 MedicalXpress article highlights a sobering reality: over 90% of medical treatments lack strong evidence, often leaving clinicians unable to definitively state whether interventions help or harm. While this observation is broadly accurate, the piece falls short by treating the evidence crisis as uniform across medicine rather than examining how it is profoundly amplified in pediatric care due to unique physiological, ethical, and structural barriers. Children are not simply smaller versions of adults; their developing organs, metabolic pathways, immune systems, and growth processes create distinct pharmacokinetic and pharmacodynamic responses that render adult-derived data unreliable.

A 2020 analysis published in JAMA Pediatrics reviewed 50 major pediatric clinical practice guidelines and determined that only 14% of recommendations were based on high-quality evidence from randomized controlled trials (RCTs), with most relying on observational studies or expert consensus. This review assessed over 1,000 cited studies, noting frequent small sample sizes (often under 200 participants) and incomplete conflict-of-interest reporting, though industry sponsorship appeared in roughly 30% of supporting trials. Similarly, a 2022 Cochrane systematic review of common pediatric interventions found a median sample size of just 85 participants across included RCTs, with high risk of bias in the majority of trials and limited long-term safety data.

These findings connect to entrenched patterns of inadequate pediatric research. Ethical constraints around informed consent and the vulnerability of minors make large-scale RCTs difficult to conduct, while pharmaceutical companies often avoid pediatric trials due to smaller market sizes, higher regulatory requirements, and liability concerns. The result is widespread off-label prescribing, with observational cohort studies (such as a 2021 multicenter analysis of over 5,000 pediatric inpatient prescriptions) showing rates exceeding 60% in intensive care settings. Such observational data, while useful for identifying patterns, lacks the causal rigor of well-powered RCTs and cannot fully account for age-specific adverse effects, as tragically demonstrated in historical cases like chloramphenicol-induced gray baby syndrome in neonates.

The original coverage misses these critical connections: the systemic underfunding of pediatric-specific research relative to disease burden, the historical exclusion of children from clinical trials, and the persistent failure of regulatory incentives like the Pediatric Research Equity Act to close the evidence gap. This is not merely a knowledge deficit but a structural failure that exposes children to unknown risks while delaying effective, tailored interventions. Addressing it requires innovative trial designs (such as adaptive platforms), increased non-industry funding, and recognition that evidence-based medicine in pediatrics demands dedicated, child-specific science rather than extrapolation.